REGN - Regeneron Pharmaceuticals, Inc.
This page shows which of the focused investors we track hold REGN and how their positions changed, so you can see how much conviction the group has in the stock.
In Q2 2025 it was held by 4 managers with an aggregate reported value of $2.21B, which is 0.19% of the combined portfolio.
As of Q2 2025, 4 tracked institutional managers held REGN (Regeneron Pharmaceuticals, Inc.) with an aggregate reported value of $2.21B — 0.19% of the combined AlphaBaseline portfolio.
Get email alerts when a tracked manager trades REGN — sign in or create a free account.
- Source
- Curated SEC 13F filings
- Period
- Q2 2025
- Ticker
- REGN
13F data is delayed and excludes shorts/non-13F assets.
Long holders
| 1 | Dodge & Cox - Dodge & Cox | 1.13% | Add +64.6% | 3,826,283 | $2.01B |
| 2 | Mason Hawkins - Southeastern Asset Management | 4.25% | Add +39.8% | 160,581 | $84.31M |
| 3 | Michael Burry - Scion Asset Management | 14.00% | New | 15,000 | $7.88M |
Call holders — bullish via leverage
1 manager holds call options on REGN — a right to buy at strike. Notional value, not premium.
| 1 | Michael Burry - Scion Asset Management | New | 200,000 | $105M |
Loading holder history for REGN…